Generation of tumor-specific CTLs from melanoma patients by using peripheral blood stimulated with allogeneic melanoma tumor cell lines: Fine specificity and MART-1 melanoma antigen recognition

E. J. Stevens, L. Jacknin, P. F. Robbins, Y. Kawakami, M. El Gamil, S. A. Rosenberg, J. R. Yannelli

Research output: Contribution to journalArticle

Abstract

PBLs were isolated from 13 patients with metastatic melanoma. Mixed lymphocyte tumor cell cultures (ML TCs) were established (15 times) by using irradiated HLA-matched (one class I locus) allogeneic melanoma tumor cell lines (13 times) or autologous melanoma tumor cell lines (two times) in medium containing 120 IU/ml IL-2 and 100 IU/ml IL-4. PBLs grew to levels that could be assessed for functional reactivity 9 of 15 times. In seven of nine cases, CD3+CD8+ CTLs grew from MLTCs that were tumor specific; five were restricted by HLA-A2 and two were restricted by HLA-A24. Four of the tumor- specific CTL lines lysed autologous fresh tumor cells. Tumor-specific CTLs from two of three patients had cytolytic activity identical with tumor- infiltrating lymphocytes (TIL) derived from tumor biopsies removed earlier and grown in high concentrations (6000 IU/ml) of IL-2. Three of the HLA-A2- restricted tumor-specific CTLs were shown to recognize 293 cells transfected with HLA-A2.1 cDNA and the gene encoding the melanoma Ag, MART-1. In addition, these CTLs recognized the T2 cell line pulsed exogenously with the peptide MART-127-35, which is the nine-amino acid immunodominant epitope of the MART-1 Ag recognized on melanoma tumor cells by nearly all HLA-A2- restricted TIL. Thus, we have demonstrated the ability to generate tumor- specific CTLs from PBLs that are similar in their reactivity to TIL. This technique obviates the need for autologous tumor tissue and suggests that PBLs contain sufficient CTL precursors for use in generating antitumor CTLs for cellular immunotherapy trials.

Original languageEnglish (US)
Pages (from-to)762-771
Number of pages10
JournalJournal of Immunology
Volume154
Issue number2
StatePublished - 1995
Externally publishedYes

Fingerprint

MART-1 Antigen
Melanoma-Specific Antigens
Tumor Cell Line
Melanoma
Neoplasms
Tumor-Infiltrating Lymphocytes
HLA-A2 Antigen
Interleukin-2
HLA-A24 Antigen
Immunodominant Epitopes
Interleukin-4
Immunotherapy
Complementary DNA
Cell Culture Techniques

ASJC Scopus subject areas

  • Immunology

Cite this

Generation of tumor-specific CTLs from melanoma patients by using peripheral blood stimulated with allogeneic melanoma tumor cell lines : Fine specificity and MART-1 melanoma antigen recognition. / Stevens, E. J.; Jacknin, L.; Robbins, P. F.; Kawakami, Y.; El Gamil, M.; Rosenberg, S. A.; Yannelli, J. R.

In: Journal of Immunology, Vol. 154, No. 2, 1995, p. 762-771.

Research output: Contribution to journalArticle

Stevens, E. J. ; Jacknin, L. ; Robbins, P. F. ; Kawakami, Y. ; El Gamil, M. ; Rosenberg, S. A. ; Yannelli, J. R. / Generation of tumor-specific CTLs from melanoma patients by using peripheral blood stimulated with allogeneic melanoma tumor cell lines : Fine specificity and MART-1 melanoma antigen recognition. In: Journal of Immunology. 1995 ; Vol. 154, No. 2. pp. 762-771.
@article{f656bbb43b5142ea94c8b84054c6c151,
title = "Generation of tumor-specific CTLs from melanoma patients by using peripheral blood stimulated with allogeneic melanoma tumor cell lines: Fine specificity and MART-1 melanoma antigen recognition",
abstract = "PBLs were isolated from 13 patients with metastatic melanoma. Mixed lymphocyte tumor cell cultures (ML TCs) were established (15 times) by using irradiated HLA-matched (one class I locus) allogeneic melanoma tumor cell lines (13 times) or autologous melanoma tumor cell lines (two times) in medium containing 120 IU/ml IL-2 and 100 IU/ml IL-4. PBLs grew to levels that could be assessed for functional reactivity 9 of 15 times. In seven of nine cases, CD3+CD8+ CTLs grew from MLTCs that were tumor specific; five were restricted by HLA-A2 and two were restricted by HLA-A24. Four of the tumor- specific CTL lines lysed autologous fresh tumor cells. Tumor-specific CTLs from two of three patients had cytolytic activity identical with tumor- infiltrating lymphocytes (TIL) derived from tumor biopsies removed earlier and grown in high concentrations (6000 IU/ml) of IL-2. Three of the HLA-A2- restricted tumor-specific CTLs were shown to recognize 293 cells transfected with HLA-A2.1 cDNA and the gene encoding the melanoma Ag, MART-1. In addition, these CTLs recognized the T2 cell line pulsed exogenously with the peptide MART-127-35, which is the nine-amino acid immunodominant epitope of the MART-1 Ag recognized on melanoma tumor cells by nearly all HLA-A2- restricted TIL. Thus, we have demonstrated the ability to generate tumor- specific CTLs from PBLs that are similar in their reactivity to TIL. This technique obviates the need for autologous tumor tissue and suggests that PBLs contain sufficient CTL precursors for use in generating antitumor CTLs for cellular immunotherapy trials.",
author = "Stevens, {E. J.} and L. Jacknin and Robbins, {P. F.} and Y. Kawakami and {El Gamil}, M. and Rosenberg, {S. A.} and Yannelli, {J. R.}",
year = "1995",
language = "English (US)",
volume = "154",
pages = "762--771",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "2",

}

TY - JOUR

T1 - Generation of tumor-specific CTLs from melanoma patients by using peripheral blood stimulated with allogeneic melanoma tumor cell lines

T2 - Fine specificity and MART-1 melanoma antigen recognition

AU - Stevens, E. J.

AU - Jacknin, L.

AU - Robbins, P. F.

AU - Kawakami, Y.

AU - El Gamil, M.

AU - Rosenberg, S. A.

AU - Yannelli, J. R.

PY - 1995

Y1 - 1995

N2 - PBLs were isolated from 13 patients with metastatic melanoma. Mixed lymphocyte tumor cell cultures (ML TCs) were established (15 times) by using irradiated HLA-matched (one class I locus) allogeneic melanoma tumor cell lines (13 times) or autologous melanoma tumor cell lines (two times) in medium containing 120 IU/ml IL-2 and 100 IU/ml IL-4. PBLs grew to levels that could be assessed for functional reactivity 9 of 15 times. In seven of nine cases, CD3+CD8+ CTLs grew from MLTCs that were tumor specific; five were restricted by HLA-A2 and two were restricted by HLA-A24. Four of the tumor- specific CTL lines lysed autologous fresh tumor cells. Tumor-specific CTLs from two of three patients had cytolytic activity identical with tumor- infiltrating lymphocytes (TIL) derived from tumor biopsies removed earlier and grown in high concentrations (6000 IU/ml) of IL-2. Three of the HLA-A2- restricted tumor-specific CTLs were shown to recognize 293 cells transfected with HLA-A2.1 cDNA and the gene encoding the melanoma Ag, MART-1. In addition, these CTLs recognized the T2 cell line pulsed exogenously with the peptide MART-127-35, which is the nine-amino acid immunodominant epitope of the MART-1 Ag recognized on melanoma tumor cells by nearly all HLA-A2- restricted TIL. Thus, we have demonstrated the ability to generate tumor- specific CTLs from PBLs that are similar in their reactivity to TIL. This technique obviates the need for autologous tumor tissue and suggests that PBLs contain sufficient CTL precursors for use in generating antitumor CTLs for cellular immunotherapy trials.

AB - PBLs were isolated from 13 patients with metastatic melanoma. Mixed lymphocyte tumor cell cultures (ML TCs) were established (15 times) by using irradiated HLA-matched (one class I locus) allogeneic melanoma tumor cell lines (13 times) or autologous melanoma tumor cell lines (two times) in medium containing 120 IU/ml IL-2 and 100 IU/ml IL-4. PBLs grew to levels that could be assessed for functional reactivity 9 of 15 times. In seven of nine cases, CD3+CD8+ CTLs grew from MLTCs that were tumor specific; five were restricted by HLA-A2 and two were restricted by HLA-A24. Four of the tumor- specific CTL lines lysed autologous fresh tumor cells. Tumor-specific CTLs from two of three patients had cytolytic activity identical with tumor- infiltrating lymphocytes (TIL) derived from tumor biopsies removed earlier and grown in high concentrations (6000 IU/ml) of IL-2. Three of the HLA-A2- restricted tumor-specific CTLs were shown to recognize 293 cells transfected with HLA-A2.1 cDNA and the gene encoding the melanoma Ag, MART-1. In addition, these CTLs recognized the T2 cell line pulsed exogenously with the peptide MART-127-35, which is the nine-amino acid immunodominant epitope of the MART-1 Ag recognized on melanoma tumor cells by nearly all HLA-A2- restricted TIL. Thus, we have demonstrated the ability to generate tumor- specific CTLs from PBLs that are similar in their reactivity to TIL. This technique obviates the need for autologous tumor tissue and suggests that PBLs contain sufficient CTL precursors for use in generating antitumor CTLs for cellular immunotherapy trials.

UR - http://www.scopus.com/inward/record.url?scp=0028847576&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028847576&partnerID=8YFLogxK

M3 - Article

C2 - 7814882

AN - SCOPUS:0028847576

VL - 154

SP - 762

EP - 771

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 2

ER -